Clinical Trial Update: A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of CS1001 in combination with regorafenib for advanced or refractory solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• CS1001
• Regorafenib (regorafenib)

Snippet

Sponsor: CStone Pharmaceuticals | Conditions: Advanced Refractory Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED